Analytical Data
-
基因名
BTK
-
简介
The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Biotinylated, C481S, sf9, His, Avi) is the recombinant human-derived BTK, expressed by Sf9 insect cells, with His, Avi labeled tag.
- Application
-
别名
BTK; Bruton agammaglobulinemia tyrosine kinase; tyrosine-protein kinase BTK;
-
种属
Human
-
表达系统
Baculovirus
-
标签
N-8*His;N-Avi
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q06187-1
-
表达区间
A2-S659, C481S
-
蛋白长度
Full Length of Isoform-1 Mature Protein
-
分子量
80.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BTK, or Bruton's tyrosine kinase, plays a crucial role in the signaling pathways of B-cells and myeloid cells, making it a significant focus in immunology and oncology research. Its dysfunction is linked to several immunodeficiencies and lymphoid malignancies, including X-linked agammaglobulinemia (XLA) and certain types of leukemia and lymphoma. The exploration of BTK as a therapeutic target has gained momentum, particularly with the development of BTK inhibitors, which have shown promise in treating B-cell malignancies by interrupting aberrant signaling pathways. Researchers have also been investigating BTK's potential in modulating immune responses, which could lead to innovative treatments for autoimmune diseases. The recombinant production of BTK protein is essential for understanding its structure-function relationships and for developing targeted inhibitors. By studying the recombinant BTK, scientists aim to elucidate its mechanism of action and identify key regulatory domains. This knowledge can facilitate the design of novel therapeutic agents, enhance our understanding of B-cell biology, and ultimately inform clinical strategies to combat BTK-associated disorders.
